Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas

Hsu-Ping Kuo, PhD, Sidney Hsieh, MSc, Jennifer Whang, PhD, Yujun Huang, PhD, Mint Sirisawad, BS, Betty Y. Chang, PhD

Blood (2016) 128 (22): 4140.

https://doi.org/10.1182/blood.V128.22.4140.4140

Published: 2016

Journal Articles

The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma

Hsu-Ping Kuo, Sidney Hsieh, Karl J. Schweighofer, Leo WK Cheung, Shiquan Wu, Mutiah Apatira, Mint Sirisawad, Karl Eckert, Yu Liang, Jeff Hsu, Betty Y. Chang, PhD

Blood (2015) 126 (23): 699.

https://doi.org/10.1182/blood.V126.23.699.699

Published: 2015

Journal Articles

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Andrew M. Evens, DO, MSc, Julie M Vose, MD, MBA, Wael Harb, MD, Leo I. Gordon, MD, Robert Langdon, MD, Barbara Grant, MD, Julian Sprague, MD, PhD, Clara Plasencia, MS, Mint Sirisawad, MS, Jeanne Yue, MS, Ying Luan, PhD, Aaron Siek, BS, Lei Zhou, MD, Sriram Balasubramanian, PhD, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 55.

https://doi.org/10.1182/blood.V120.21.55.55

Published: 2012

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-κB pathways

Sriram Balasubramanian, PhD, Richard Crowley, MS, Mint Sirisawad, MS, Patti Thiemann, MS, Jun Chen, PhD, Joseph J. Buggy, PhD

Blood (2011) 118 (21): 4969.

https://doi.org/10.1182/blood.V118.21.4969.4969

Published: 2011

Journal Articles

The Histone Deacetylase (HDAC) Inhibitor PCI-24781 Decreases Pro-Inflammatory Cytokine Secretion In Vitro and In Vivo and Protects Against Endotoxemia In a Sepsis Model

Sriram Balasubramanian, PhD, Mint Sirisawad, MS, Susanne Steggerda, PhD, Wangsen Cao, MD, PhD, Charles Lowenstein, MD, Joseph J Buggy, PhD

Blood (2010) 116 (21): 3914.

https://doi.org/10.1182/blood.V116.21.3914.3914

Published: 2010

Journal Articles

A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.

Daniel A Pollyea, MD, Sonali Smith, MD, Nathan Fowler, MD, Thomas E Boyd, MD, Ashley M Smith, BA, Mint Sirisawad, BS, Lee A Honigberg, PhD, Ahmed Hamdy, MD, Ranjana Advani, MD

Blood (2009) 114 (22): 3713.

https://doi.org/10.1182/blood.V114.22.3713.3713

Published: 2009

Journal Articles

Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.

Andrew M Evens, DO, MSc, Weiyun Ai, MD, PhD, Sriram Balasubramanian, PhD, Mint Sirisawad, M.S., Chitra Mani, PhD, Martha Guerra, RN, Nancy Szakacs, BS, MBA, David Loury, PhD, Joseph J Buggy, Ph.D., Ahmed Hamdy, MD, Julie M. Vose, M.D., Nancy L Bartlett, MD

Blood (2009) 114 (22): 2726.

https://doi.org/10.1182/blood.V114.22.2726.2726

Published: 2009

Journal Articles

The Histone Deacetylase-8 (HDAC8) Selective Inhibitor PCI-34051 Decreases Interleukin-1 Beta Secretion in Vitro and Reduces Inflammation in Vivo

Sriram Balasubramanian, PhD, Susanne Steggerda, Ph.D., Mint Sirisawad, M.S., Marshall Schreeder, Luke Doiron, Joseph J Buggy, Ph.D.

Blood (2008) 112 (11): 2581.

https://doi.org/10.1182/blood.V112.11.2581.2581

Published: 2008

Journal Articles

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Savita Bhalla, PhD, Kevin David, MD, Lauren Mauro, MD, Sheila Prachand, MS, Mint Sirisawad, Sriram Balasubramanian, PhD, Richard A. Miller, MD, Joseph Buggy, PhD, Leo I. Gordon, MD, Andrew M. Evens, DO, MS

Blood (2007) 110 (11): 3589.

https://doi.org/10.1182/blood.V110.11.3589.3589

Published: 2007

Journal Articles

Development of RAD51 as Biomarker for Sensitivity to the Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.

Sriram Balasubramanian, PhD, Shanthi Adimoolam, PhD, Mint Sirisawad, MS, Andrew M. Evens, DO, Leo I. Gordon, MD, Richard Miller, MD, Joseph J. Buggy, PhD

Blood (2007) 110 (11): 1377.

https://doi.org/10.1182/blood.V110.11.1377.1377

Published: 2007

Journal Articles

Histone Deacetylase Inhibitor, PCI-24781, Induces Growth Inhibition and Apoptosis in Hematopoietic Tumor-Derived Cell Lines and Primary Leukemia Cells.

Joseph Buggy, PhD, Sriram Balasubramanian, PhD, Jason Ramos, PhD, Mint Sirisawad, MS, Louie Naumovski, MD, PhD

Blood (2006) 108 (11): 4399.

https://doi.org/10.1182/blood.V108.11.4399.4399

Published: 2006

Journal Articles

Motexafin Gadolinium Causes Apoptosis in Lymphoma Cells by Increasing Intracellular Free Zinc and Disrupting Redox Balance.

Darren Magda, PhD, Philip Lecane, PhD, Mazen W. Karaman, PhD, Mint Sirisawad, PhD, Louie Naumovski, MD, PhD, Richard A. Miller, MD, Joseph G. Hacia, PhD

Blood (2005) 106 (11): 4827.

https://doi.org/10.1182/blood.V106.11.4827.4827

Published: 2005

Journal Articles

Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines: Role of Elevated Intracellular Calcium.

Jun Chen, PhD, Jason Ramos, PhD, Mint Sirisawad, BS, Richard A. Miller, MD, Louie Naumovski, MD-PhD

Blood (2005) 106 (11): 4829.

https://doi.org/10.1182/blood.V106.11.4829.4829

Published: 2005

Journal Articles

Motexafin Gadolinium and Other Metallotexaphyrins Upregulate Heme Oxygenase-1.

Mint Sirisawad, Jun Chen, Jason Ramos, Richard A. Miller, Louie Naumovski

Blood (2005) 106 (11): 4468.

https://doi.org/10.1182/blood.V106.11.4468.4468

Published: 2005

Journal Articles

Motexafin Gadolinium Upregulates pAkt Levels and Synergizes with Inhibitors of Akt Phosphorylation.

Jason Ramos, PhD, Mint Sirisawad, BS, Richard A. Miller, Louie Naumovski, MD-PhD

Blood (2005) 106 (11): 4275.

https://doi.org/10.1182/blood.V106.11.4275.4275

Published: 2005

Journal Articles

Growth Inhibition or Apoptosis after Treatment with Motexafin Gadolinium and Celecoxib Is Cell Line Dependent and Correlates with p27 Levels.

Jason Ramos, PhD, Mint Sirisawad, BS, Jun Chen, PhD, Richard A. Miller, MD, Louie Naumovski, MD-PhD

Blood (2005) 106 (11): 4296.

https://doi.org/10.1182/blood.V106.11.4296.4296

Published: 2005

Journal Articles

Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines.

Jun Chen, PhD, Jason Ramos, PhD, Mint Sirisawad, BA, Richard A. Miller, MD, Louie Naumovski, MD-PhD

Blood (2004) 104 (11): 2296.

https://doi.org/10.1182/blood.V104.11.2296.2296

Published: 2004

Journal Articles

Sapphyrins Exhibit Tumor Selectivity and Efficacy in Animal Models of Hematologic Malignancies.

Louie Naumovski, MD-PhD, Mint Sirisawad, BA, Philip Lecane, PhD, Jason Ramos, PhD, Darren Magda, PhD, Zhong Wang, PhD, Patti Thiemann, BS, Garry Boswell, PharmD, Dong-Gyu Cho, BS, Jonathan Sessler, PhD, Richard A. Miller, MD

Blood (2004) 104 (11): 2501.

https://doi.org/10.1182/blood.V104.11.2501.2501

Published: 2004

Journal Articles

Motexafin Gadolinium, a Redox Mediator, Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells and Is Additive or Synergistic with Fludarabine.

Louie Naumovski, MD-PhD, Nancy D. Bone, BA, Mint Sirisawad, BA, Richard Miller, MD, Diane F. Jelinek, PhD, Renee C. Tschumper, BA, Neil E. Kay, MD

Blood (2004) 104 (11): 4799.

https://doi.org/10.1182/blood.V104.11.4799.4799

Published: 2004

Journal Articles

Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors.

Louie Naumovski, MD-PhD, Jason Ramos, PhD, Jun Chen, PhD, Mint Sirisawad, BA, David Lucas, PhD, John C. Byrd, MD, Richard A. Miller, MD

Blood (2004) 104 (11): 3406.

https://doi.org/10.1182/blood.V104.11.3406.3406

Published: 2004

NARROW

Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas

The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-κB pathways

The Histone Deacetylase (HDAC) Inhibitor PCI-24781 Decreases Pro-Inflammatory Cytokine Secretion In Vitro and In Vivo and Protects Against Endotoxemia In a Sepsis Model

A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.

Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.

The Histone Deacetylase-8 (HDAC8) Selective Inhibitor PCI-34051 Decreases Interleukin-1 Beta Secretion in Vitro and Reduces Inflammation in Vivo

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Development of RAD51 as Biomarker for Sensitivity to the Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.

Histone Deacetylase Inhibitor, PCI-24781, Induces Growth Inhibition and Apoptosis in Hematopoietic Tumor-Derived Cell Lines and Primary Leukemia Cells.

Motexafin Gadolinium Causes Apoptosis in Lymphoma Cells by Increasing Intracellular Free Zinc and Disrupting Redox Balance.

Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines: Role of Elevated Intracellular Calcium.

Motexafin Gadolinium and Other Metallotexaphyrins Upregulate Heme Oxygenase-1.

Motexafin Gadolinium Upregulates pAkt Levels and Synergizes with Inhibitors of Akt Phosphorylation.

Growth Inhibition or Apoptosis after Treatment with Motexafin Gadolinium and Celecoxib Is Cell Line Dependent and Correlates with p27 Levels.

Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines.

Sapphyrins Exhibit Tumor Selectivity and Efficacy in Animal Models of Hematologic Malignancies.

Motexafin Gadolinium, a Redox Mediator, Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells and Is Additive or Synergistic with Fludarabine.

Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only